Anakinra is safe in HSCT recipients and reinforces the mucosal barrier to control acute complications of high-dose melphalan: results from the AFFECT-1 (Phase IIA) trial and preclinical efficacy study

Hannah R. Wardill, Charlotte M. E. De Mooij, Walter J. F. M. van der Velden, Hermie J. M. Harmsen, Wim J. E. Tissing, Nicole M. A. Blijlevens

Research output: Contribution to journalMeeting AbstractAcademic

Original languageEnglish
Pages (from-to)115-115
Number of pages1
JournalAsia-Pacific journal of clinical oncology
Issue numberS9
Publication statusPublished - Nov-2021

Cite this